argenx SE halted its Phase 3 UNITY study for futility, leading to a 10% drop in its stock price. SueWallSt notifies investors of a pending investigation into potential securities law violations.
Why it matters. argenx shareholders who lost money due to the stock price drop may be eligible for compensation through the investigation.
argenx said it would discontinue the study.
Shares fell approximately $96.73 per share, or about 10.42% in pre-market trading on October 8, 2026
When the Company disclosed that the study would be discontinued for futility, the stock price declined sharply.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- argenx SE (NASDAQ: ARGX) stock dropped more than 10% in pre-market trading on October 8, 2026, when the Company halted its Phase 3 UNITY study of subcutaneous Vyvgart in Sjögren's disease for futility. If you bought ARGX and are now holding…
The same morning, argenx also reported positive Phase 2 results for FB102 in celiac disease. ARGX shares fell anyway. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of argenx shareholders who suffered losses in the decl…
